News & Updates
Filter by Specialty:
Peg lambda cuts hospitalization, ER visits in COVID-19 outpatients
Early treatment with a single dose of pegylated recombinant IL-29 type III interferon (IFN), otherwise known as peg lambda, significantly reduced clinical events in the phase III TOGETHER study evaluating mostly vaccinated, acutely symptomatic COVID-19 outpatients.
Peg lambda cuts hospitalization, ER visits in COVID-19 outpatients
09 Mar 2023Lower torso exercise plus respiratory training beneficial in asthma
Breathing exercise devices such as a conventional threshold loading training (TLT) device or an innovative respiratory training (IRT) device, when used in combination with lower torso sports training (LTST), proved beneficial in improving pulmonary function, exercise capacity, and quality of life (QoL) in individuals with asthma, a study suggests. However, IRT trumped TLT in terms of improvements in some respiratory and physical performance variables.
Lower torso exercise plus respiratory training beneficial in asthma
07 Mar 2023Long-term exposure to ambient air pollution ups risk of pneumonia
Individuals with long-term exposure to air pollutants appear to be at higher risk of pneumonia, with the risk being more pronounced among smokers, as shown in a study.
Long-term exposure to ambient air pollution ups risk of pneumonia
24 Feb 2023VV116 noninferior to nirmatrelvir-ritonavir for COVID-19
Early administration of oral VV116 was noninferior to nirmatrelvir-ritonavir in shortening the time to sustained clinical recovery in individuals with mild-to-moderate COVID-19 who were at high risk for progression to severe disease, a phase III trial has shown. VV116 also had fewer safety issues than nirmatrelvir-ritonavir.
VV116 noninferior to nirmatrelvir-ritonavir for COVID-19
21 Feb 2023Gefitinib plus chemotherapy improves survival outcomes in mutated NSCLC brain metastases
Treatment with the combination of gefitinib and chemotherapy appears to yield significant increases in progression-free survival (PFS), intracranial PFS, and overall survival in patients with untreated EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases as compared gefitinib monotherapy, according to the results of the phase III GAP BRAIN study.
Gefitinib plus chemotherapy improves survival outcomes in mutated NSCLC brain metastases
18 Feb 2023Childhood asthma, T1D, IBD: Do they have shared mechanisms?
Children diagnosed with asthma between ages 5 and 7 years may have an increased risk of developing type 1 diabetes (T1D) and inflammatory bowel diseases (IBD; Crohn’s disease and ulcerative colitis), a Danish nationwide registry study suggests.